First Line Anti-tuberculosis Medication for Pregnant Women

Gudisa Bereda

doi:doi:10.11648/j.ijpc.20220802.11

| Peer-Reviewed

First Line Anti-tuberculosis Medication for Pregnant Women

Gudisa Bereda

Published in International Journal of Pharmacy and Chemistry (Volume 8, Issue 2)

Received: 31 December 2021 Accepted: 22 January 2022 Published: 14 April 2022

Views: Downloads:

Download PDF

Share This Article

Twitter
Linked In
Facebook

Abstract

Tuberculosis is more sophisticated to diagnose in pregnant women contract the diseases because tuberculosis clinical manifestations suchlike tiredness, difficulty of breathing, sweating, weakness, coughing, and rare body temperature that is higher than normal are identical to the physiology of pregnant women changed during pregnancy. According to the United States food and drug administration risk classification of medicines among pregnancy; the four first line anti-tuberculosis medications are classified as category B and category C. The 1st line regimen management for pulmonary and extrapulmonary tuberculosis does not distinctive during pregnant and nonpregnant women. The WHO recommends 8 weeks of isoniazid, rifampicin, pyrazinamide, and ethambutol for intensive phase, followed by 16 weeks of isoniazid and rifampicin for continuation phase. This regimen is safe to use during pregnancy. Rifampicin is a category C medicine. Bleeding differentiated to hypoprothrominemia has been reported in child less than 1 year and mother following the usage of rifampicin in pregnancy period begins at 28 weeks until birth. The usage of rifampicin is recommended for pregnant women with vitamin K for management tuberculosis, should be given to the breastfeeding women and the child less than 1 year postnatal if rifampicin is given to the pregnant mother in the last few weeks. Ethambutol is pregnancy class B medicine. Ethambutol highly concentrated in fetus plasma concentration which can be as high as thirty percent of the plasma concentration of drugs in mother because ethambutol easily crosses the placental barrier. Ethambutol freely crosses the placenta with a cord to maternal serum ratio of 0.75.

Published in	International Journal of Pharmacy and Chemistry (Volume 8, Issue 2)
DOI	10.11648/j.ijpc.20220802.11
Page(s)	20-23
Creative Commons	This is an Open Access article, distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution and reproduction in any medium or format, provided the original work is properly cited.
Copyright	Copyright © The Author(s), 2022. Published by Science Publishing Group

Keywords

Anti-tuberculosis Medication, First Line, Pregnant Women

References

[1]	O. M. Loto and I. Awowole. Tuberculosis in Pregnancy: A Review. Journal of Pregnancy Volume 2012, Article ID 379271, 7 pages doi: 10.1155/2012/379271.
[2]	“2010/2011 tuberculosis global fact; World Health Organisation,” http://www.who.int/tb/country/en/index.html, Nov. 2010.
[3]	Nguyen HT et al. Tuberculosis care for pregnant women: a systematic review. BMC Infectious Diseases 2014, 14: 617. http://www.biomedcentral.com/1471-2334/14/617.
[4]	Bergeron KG, Bonebrake RG, Allen C, Gray CJ: Latent tuberculosis in pregnancy: screening and treatment. Curr Womens Health Reports 2003, 3: 303–308.
[5]	Nhan-Chang CL, Jones TB: Tuberculosis in pregnancy. Clin Obstet Gynecol 2010, 53: 311–321.
[6]	Rai DK. Tuberculosis in pregnancy. East J Med Sci. 2016; 1 (2): 42-45.
[7]	Repossi AC, Bothamley GH. Tuberculosis and pregnancy: an updatedsystematic review. Pulm Res Respir Med Open J. 2015; 2 (1): 63-68. doi: 10.17140/PRRMOJ-2-109.
[8]	Bothamley GH. Screening for tuberculosis in pregnancy. Expert. Rev. Obstet. Gynecol. 2012; 7 (4): 387-395.
[9]	Bedewi N, Sisay M, Edessa D. Drug utilization pattern among pregnant women attending maternal and child health clinic of tertiary hospital in eastern Ethiopia: Consideration of toxicological perspectives. BMC Res Notes. 2018; 11: 858.
[10]	Kaplan YC. Drug use and/or exposure in pregnancy: Presence of risk versus quantity of risk. J Turkish Ger Gynecol Assoc. 2015; 16 (2): 123– 123.
[11]	Whitehouse Station, New Jersey: Merck; 2016. Available at: www.merck.com/product/usa/pi_circulars/z/zepatier/zepatier_pi.pdf. Accessed February 13, 2016.
[12]	Yondelis (trabectedin) prescribing information. Horsham, Pennsylvania: Janssen Biotech; 2015. Available at: www.yondelis.com/prescribing-information.pdf. Accessed February 13, 2016.
[13]	Beroukhim K, Abrouk M, Farahnik B. Impact of the Pregnancy and Lactation Labeling Rule (PLLR) on practicing dermatologists. Dermatol Online J 2015; 21 (11). pii: 13030/qt46c4m2tw.
[14]	Veiby G, Daltveit AK, Schjølberg S, Stoltenberg C, Øyen AS, Vollset SE, Engelsen BA, Gilhus NE. Exposure to antiepileptic drugs in utero and child development: a prospective population-based study. Epilepsia. 2013; 54 (8): 1462–72.
[15]	Gilboa SM, Broussard CS, Devine OJ, Duwe KN, Flak AL, Boulet SL, Moore CA, Werler MM, Honein MA. Influencing clinical practice regarding the use of antiepileptic medications during pregnancy: modeling the potential impact on the prevalences of spina bifida and cleft palate in the United States. Am J Med Genet C: Semin Med Genet. 2011; 157C (3): 234–46.
[16]	Viguera AC, Whitfield T, Baldessarini RJ, Newport DJ, Stowe Z, Reminick A, Zurick A, Cohen LS. Risk of recurrence in women with bipolar disorder during pregnancy: prospective study of mood stabilizer discontinuation. Am J Psychiatry. 2007; 164 (12): 1817–24. quiz 1923.
[17]	Harden CL, Hopp J, Ting TY, Pennell PB, French JA, Hauser WA, et al. Practice parameter update: management issues for women with epilepsy--focus on pregnancy (an evidencebased review): obstetrical complications and change in seizure frequency: report of the Quality Standards Subcommittee and Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology and American Epilepsy Society. Neurology 2009; 73 (2): 126–32. 8.
[18]	World Health Organization. Treatment of tuberculosis guidelines. 4th edition, 2010. http://whqlibdoc.who.int/publications/2010/9789241547833_eng.pdf?ua=1. Accessed September 12, 2014.
[19]	Arbex MA, Varella MCL, Siqueira HR et al. Antituberculosis drugs: Drug interactions, adverse effects, and use in special situations. Part 1: First-line drugs. J Bras Pneumol. 2010; 36 (5): 626-640.
[20]	Blumberg HM, Burman WJ, Chaisson RE, Daley CL, Etkind SC, Friedman LN, et al. American Thoracic Society/ Centers for Disease Control and Prevention/Infectious Diseases Society of America: treatment of tuberculosis. Am J Respir Crit Care Med. 2003; 167 (4): 603-62.
[21]	World Health Organization. Treatment of Tuberculosis: Guidelines for National Programmes. Geneva: World Health Organization; 2003.
[22]	Nardiello S, Pizzella T, Ariviello R. Risks of antibacterial agents in pregnancy [Article in Italian]. Infez Med. 2002; 10 (1): 8-15.
[23]	Ormerod P. Tuberculosis in pregnancy and the puerperium. Thorax 2001; 56: 494–499.
[24]	World Health Organization. The Treatment of Tuberculosis Guidelines. Geneva: World Health Organization; 2010.
[25]	Rakotoson JL, Randriamanana D, Rakotomizao JR, Andrianasolo R, Rakotoarivelo R, Andrianarisoa AC. Severe systemic lupus erythematosus induced by isoniazid [Article in French]. Rev Pneumol Clin. 2009; 65 (6): 361-4.
[26]	Brasil. Ministério da Saúde. Fundação Nacional de Saúde. Centro de Referência Professor Hélio Fraga; Sociedade Brasileira de Pneumologia e Tisiologia. Controle da tuberculose: uma proposta de integração ensino-serviço. Rio de Janeiro: FUNASA/CRPHF/SBPT; 2002.
[27]	H. M. Blumberg, W. J. Burman, R. E. Chaisson et al., “American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America: treatment of tuberculosis,” American Journal of Respiratory and Critical Care Medicine, vol. 167, no. 4, pp. 603–662, 2003.
[28]	Anon, “Treatment of tuberculosis,” MMWR Recommendations and Reports, vol. 52, pp. 1–77, 2003.
[29]	J. G. Bartlett, “Guidelines section,” Infectious Diseases in Clinical Practice, vol. 11, pp. 467–471, 2002.

Cite This Article

Plain Text BibTeX RIS

APA Style

Gudisa Bereda. (2022). First Line Anti-tuberculosis Medication for Pregnant Women. International Journal of Pharmacy and Chemistry, 8(2), 20-23. https://doi.org/10.11648/j.ijpc.20220802.11

Copy | Download

ACS Style

Gudisa Bereda. First Line Anti-tuberculosis Medication for Pregnant Women. Int. J. Pharm. Chem. 2022, 8(2), 20-23. doi: 10.11648/j.ijpc.20220802.11

Copy | Download

AMA Style

Gudisa Bereda. First Line Anti-tuberculosis Medication for Pregnant Women. Int J Pharm Chem. 2022;8(2):20-23. doi: 10.11648/j.ijpc.20220802.11

Copy | Download

@article{10.11648/j.ijpc.20220802.11,
  author = {Gudisa Bereda},
  title = {First Line Anti-tuberculosis Medication for Pregnant Women},
  journal = {International Journal of Pharmacy and Chemistry},
  volume = {8},
  number = {2},
  pages = {20-23},
  doi = {10.11648/j.ijpc.20220802.11},
  url = {https://doi.org/10.11648/j.ijpc.20220802.11},
  eprint = {https://article.sciencepublishinggroup.com/pdf/10.11648.j.ijpc.20220802.11},
  abstract = {Tuberculosis is more sophisticated to diagnose in pregnant women contract the diseases because tuberculosis clinical manifestations suchlike tiredness, difficulty of breathing, sweating, weakness, coughing, and rare body temperature that is higher than normal are identical to the physiology of pregnant women changed during pregnancy. According to the United States food and drug administration risk classification of medicines among pregnancy; the four first line anti-tuberculosis medications are classified as category B and category C. The 1st line regimen management for pulmonary and extrapulmonary tuberculosis does not distinctive during pregnant and nonpregnant women. The WHO recommends 8 weeks of isoniazid, rifampicin, pyrazinamide, and ethambutol for intensive phase, followed by 16 weeks of isoniazid and rifampicin for continuation phase. This regimen is safe to use during pregnancy. Rifampicin is a category C medicine. Bleeding differentiated to hypoprothrominemia has been reported in child less than 1 year and mother following the usage of rifampicin in pregnancy period begins at 28 weeks until birth. The usage of rifampicin is recommended for pregnant women with vitamin K for management tuberculosis, should be given to the breastfeeding women and the child less than 1 year postnatal if rifampicin is given to the pregnant mother in the last few weeks. Ethambutol is pregnancy class B medicine. Ethambutol highly concentrated in fetus plasma concentration which can be as high as thirty percent of the plasma concentration of drugs in mother because ethambutol easily crosses the placental barrier. Ethambutol freely crosses the placenta with a cord to maternal serum ratio of 0.75.},
 year = {2022}
}

Copy | Download

TY  - JOUR
T1  - First Line Anti-tuberculosis Medication for Pregnant Women
AU  - Gudisa Bereda
Y1  - 2022/04/14
PY  - 2022
N1  - https://doi.org/10.11648/j.ijpc.20220802.11
DO  - 10.11648/j.ijpc.20220802.11
T2  - International Journal of Pharmacy and Chemistry
JF  - International Journal of Pharmacy and Chemistry
JO  - International Journal of Pharmacy and Chemistry
SP  - 20
EP  - 23
PB  - Science Publishing Group
SN  - 2575-5749
UR  - https://doi.org/10.11648/j.ijpc.20220802.11
AB  - Tuberculosis is more sophisticated to diagnose in pregnant women contract the diseases because tuberculosis clinical manifestations suchlike tiredness, difficulty of breathing, sweating, weakness, coughing, and rare body temperature that is higher than normal are identical to the physiology of pregnant women changed during pregnancy. According to the United States food and drug administration risk classification of medicines among pregnancy; the four first line anti-tuberculosis medications are classified as category B and category C. The 1st line regimen management for pulmonary and extrapulmonary tuberculosis does not distinctive during pregnant and nonpregnant women. The WHO recommends 8 weeks of isoniazid, rifampicin, pyrazinamide, and ethambutol for intensive phase, followed by 16 weeks of isoniazid and rifampicin for continuation phase. This regimen is safe to use during pregnancy. Rifampicin is a category C medicine. Bleeding differentiated to hypoprothrominemia has been reported in child less than 1 year and mother following the usage of rifampicin in pregnancy period begins at 28 weeks until birth. The usage of rifampicin is recommended for pregnant women with vitamin K for management tuberculosis, should be given to the breastfeeding women and the child less than 1 year postnatal if rifampicin is given to the pregnant mother in the last few weeks. Ethambutol is pregnancy class B medicine. Ethambutol highly concentrated in fetus plasma concentration which can be as high as thirty percent of the plasma concentration of drugs in mother because ethambutol easily crosses the placental barrier. Ethambutol freely crosses the placenta with a cord to maternal serum ratio of 0.75.
VL  - 8
IS  - 2
ER  -

Copy | Download

Author Information

Gudisa Bereda

Department of Pharmacy, Negelle Health Science College, Guji, Ethiopia

Download PDF

Sections

Plain Text BibTeX RIS

APA Style

Gudisa Bereda. (2022). First Line Anti-tuberculosis Medication for Pregnant Women. International Journal of Pharmacy and Chemistry, 8(2), 20-23. https://doi.org/10.11648/j.ijpc.20220802.11

Copy | Download

ACS Style

Gudisa Bereda. First Line Anti-tuberculosis Medication for Pregnant Women. Int. J. Pharm. Chem. 2022, 8(2), 20-23. doi: 10.11648/j.ijpc.20220802.11

Copy | Download

AMA Style

Gudisa Bereda. First Line Anti-tuberculosis Medication for Pregnant Women. Int J Pharm Chem. 2022;8(2):20-23. doi: 10.11648/j.ijpc.20220802.11

Copy | Download

@article{10.11648/j.ijpc.20220802.11,
  author = {Gudisa Bereda},
  title = {First Line Anti-tuberculosis Medication for Pregnant Women},
  journal = {International Journal of Pharmacy and Chemistry},
  volume = {8},
  number = {2},
  pages = {20-23},
  doi = {10.11648/j.ijpc.20220802.11},
  url = {https://doi.org/10.11648/j.ijpc.20220802.11},
  eprint = {https://article.sciencepublishinggroup.com/pdf/10.11648.j.ijpc.20220802.11},
  abstract = {Tuberculosis is more sophisticated to diagnose in pregnant women contract the diseases because tuberculosis clinical manifestations suchlike tiredness, difficulty of breathing, sweating, weakness, coughing, and rare body temperature that is higher than normal are identical to the physiology of pregnant women changed during pregnancy. According to the United States food and drug administration risk classification of medicines among pregnancy; the four first line anti-tuberculosis medications are classified as category B and category C. The 1st line regimen management for pulmonary and extrapulmonary tuberculosis does not distinctive during pregnant and nonpregnant women. The WHO recommends 8 weeks of isoniazid, rifampicin, pyrazinamide, and ethambutol for intensive phase, followed by 16 weeks of isoniazid and rifampicin for continuation phase. This regimen is safe to use during pregnancy. Rifampicin is a category C medicine. Bleeding differentiated to hypoprothrominemia has been reported in child less than 1 year and mother following the usage of rifampicin in pregnancy period begins at 28 weeks until birth. The usage of rifampicin is recommended for pregnant women with vitamin K for management tuberculosis, should be given to the breastfeeding women and the child less than 1 year postnatal if rifampicin is given to the pregnant mother in the last few weeks. Ethambutol is pregnancy class B medicine. Ethambutol highly concentrated in fetus plasma concentration which can be as high as thirty percent of the plasma concentration of drugs in mother because ethambutol easily crosses the placental barrier. Ethambutol freely crosses the placenta with a cord to maternal serum ratio of 0.75.},
 year = {2022}
}

Copy | Download

TY  - JOUR
T1  - First Line Anti-tuberculosis Medication for Pregnant Women
AU  - Gudisa Bereda
Y1  - 2022/04/14
PY  - 2022
N1  - https://doi.org/10.11648/j.ijpc.20220802.11
DO  - 10.11648/j.ijpc.20220802.11
T2  - International Journal of Pharmacy and Chemistry
JF  - International Journal of Pharmacy and Chemistry
JO  - International Journal of Pharmacy and Chemistry
SP  - 20
EP  - 23
PB  - Science Publishing Group
SN  - 2575-5749
UR  - https://doi.org/10.11648/j.ijpc.20220802.11
AB  - Tuberculosis is more sophisticated to diagnose in pregnant women contract the diseases because tuberculosis clinical manifestations suchlike tiredness, difficulty of breathing, sweating, weakness, coughing, and rare body temperature that is higher than normal are identical to the physiology of pregnant women changed during pregnancy. According to the United States food and drug administration risk classification of medicines among pregnancy; the four first line anti-tuberculosis medications are classified as category B and category C. The 1st line regimen management for pulmonary and extrapulmonary tuberculosis does not distinctive during pregnant and nonpregnant women. The WHO recommends 8 weeks of isoniazid, rifampicin, pyrazinamide, and ethambutol for intensive phase, followed by 16 weeks of isoniazid and rifampicin for continuation phase. This regimen is safe to use during pregnancy. Rifampicin is a category C medicine. Bleeding differentiated to hypoprothrominemia has been reported in child less than 1 year and mother following the usage of rifampicin in pregnancy period begins at 28 weeks until birth. The usage of rifampicin is recommended for pregnant women with vitamin K for management tuberculosis, should be given to the breastfeeding women and the child less than 1 year postnatal if rifampicin is given to the pregnant mother in the last few weeks. Ethambutol is pregnancy class B medicine. Ethambutol highly concentrated in fetus plasma concentration which can be as high as thirty percent of the plasma concentration of drugs in mother because ethambutol easily crosses the placental barrier. Ethambutol freely crosses the placenta with a cord to maternal serum ratio of 0.75.
VL  - 8
IS  - 2
ER  -

Copy | Download